Cancer survival linked to cardiovascular hormone/peptide levels
the ONA take:
Cardiovascular biomarkers such as high circulating levels of cardiovascular hormones/peptides in patients with cancer are linked to shorter survival, according to research published online in Heart.
In this study, researchers sought to determine whether the cancer itself affects levels of cardiovascular hormones/peptides.
The researchers assessed circulating levels of several cardiovascular hormones; proteins indicative of inflammation; and high sensitive troponin (hsTNT), a chemical that regulates heart muscle contractions, in 555 people with a first cancer diagnosis.
None of the participants had yet undergone any drug or radiotherapy treatments that might have damaged their heart tissue. The participants were tracked for an average of 25 months.
Almost one-third of the participants died during the monitoring period. Analysis of their blood samples showed that all the hormones measured and hsTNT increased in tandem with disease severity, sometimes to levels 100 times higher than expected.
The researchers report that their findings suggest that these biomarkers were indicative of heart damage not yet clinically evident, but directly linked to the cancer progression.
Furthermore, the findings suggest that the benefits of heart failure drugs for cancer patients may extend beyond helping to reduce cardiovascular side effects of cancer treatment.
Cardiovascular biomarkers such as high circulating levels of cardiovascular hormones/peptides in cancer are linked to shorter survival.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|